PFIZER INC.
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- Public
- Established
- 1849-01-01
- Employees
- 88K
- Market Cap
- $163.3B
- Website
- http://www.pfizer.com
A 6-Month Study Of CP-690,550 Versus Tacrolimus In Kidney Transplant Patients
- First Posted Date
- 2005-03-29
- Last Posted Date
- 2013-03-12
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 61
- Registration Number
- NCT00106639
- Locations
- 🇺🇸
Pfizer Investigational Site, Milwaukee, Wisconsin, United States
Study Evaluating Biomarkers In Relapsed/Refractory Pediatric Solid Tumors
- First Posted Date
- 2005-03-23
- Last Posted Date
- 2013-02-08
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 71
- Registration Number
- NCT00106353
- Locations
- 🇷🇺
Pfizer Investigational Site, Saint Petersburg, Russian Federation
Neoadjuvant Colorectal Cancer With Unresectable Liver Metastases
Phase 2
Terminated
- Conditions
- Colorectal NeoplasmsLiver Neoplasms
- First Posted Date
- 2005-03-21
- Last Posted Date
- 2010-08-27
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 2
- Registration Number
- NCT00106054
- Locations
- 🇺🇸
Pfizer Investigational Site, Philadelphia, Pennsylvania, United States
A Research Study of CP-724,714 in Patients With HER2 Overexpressing Metastatic Breast Cancer
Phase 2
Terminated
- Conditions
- Breast NeoplasmsNeoplasm Metastasis
- First Posted Date
- 2005-02-04
- Last Posted Date
- 2010-08-27
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 25
- Registration Number
- NCT00102895
Trial Of Irinotecan In Combination With Three Methods Of Administration Of Fluoropyrimidine.
Phase 3
Completed
- Conditions
- Colorectal Neoplasms
- Interventions
- Drug: Modified Bolus 5-FU/LV with IrinotecanDrug: FOLFIRI + bevacizumabDrug: miFL + bevacizumabDrug: Infusional 5-FU/LV with Irinotecan
- First Posted Date
- 2005-01-13
- Last Posted Date
- 2010-01-12
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 547
- Registration Number
- NCT00101686
- Locations
- 🇳🇿
Pfizer Investigational Site, Wellington, New Zealand
Anti-angiogenesis Agent AG-013736 in Patients With Advanced Non-Small Cell Lung Cancer
- First Posted Date
- 2004-10-14
- Last Posted Date
- 2012-06-26
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 32
- Registration Number
- NCT00094094
- Locations
- 🇩🇪
Pfizer Investigational Site, Gauting, Germany
Anti-Angiogenesis Agent AG-013736 In Patients With Metastatic Melanoma
- First Posted Date
- 2004-10-14
- Last Posted Date
- 2012-06-26
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 32
- Registration Number
- NCT00094107
- Locations
- 🇫🇷
Pfizer Investigational Site, Paris Cedex 13, France
Study of the Anti-angiogenesis Agent AG-013736 in Patients With Metastatic Thyroid Cancer
- First Posted Date
- 2004-10-11
- Last Posted Date
- 2012-06-26
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 60
- Registration Number
- NCT00094055
- Locations
- 🇺🇸
Pfizer Investigational Site, Houston, Texas, United States
A Treatment Protocol for Patients With Gastrointestinal Stromal Tumor (GIST) Who May Derive Benefit From Treatment With SU011248
- Conditions
- Gastrointestinal Neoplasm
- First Posted Date
- 2004-10-11
- Last Posted Date
- 2012-03-09
- Lead Sponsor
- Pfizer
- Registration Number
- NCT00094029
- Locations
- 🇻🇪
Pfizer Investigational Site, Caracas, Distrito Capital, Venezuela
Study Of SU011248 In Patients With Metastatic Non-Small Cell Lung Cancer
- First Posted Date
- 2004-09-27
- Last Posted Date
- 2008-10-16
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 111
- Registration Number
- NCT00092001
- Locations
- 🇪🇸
Pfizer Investigational Site, Barcelona, Spain
© Copyright 2025. All Rights Reserved by MedPath